argenx is a global immunology company committed to improving lives of people suffering from severe autoimmune diseases. argenx developed and is commercializing the first approved neonatal Fc receptor blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
argenx
33 Arch Street
32nd Floor
Boston, MA 02110